AKTX · Akari Therapeutics PLC - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | FY 2024 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $1.46M | - | $249.0K | $667.0K | $813.0K | - | ($314.0K) | $3.31M | - | $2.28M |
| SG&A | $2.17M | - | $1.98M | $2.45M | $2.71M | - | $1.71M | $3.09M | $1.28M | $3.71M |
| Total Operating Expenses | $15.76M | - | - | - | $5.99M | - | - | - | $1.39M | - |
| D&A | - | - | - | - | - | - | - | - | - | $13.0K |
| Operating Income | ($15.76M) | - | ($7.40M) | ($3.12M) | ($3.52M) | - | ($2.93M) | ($7.45M) | - | ($5.99M) |
| Interest Expense | $61.0K | - | $100.0K | $51.0K | $55.0K | - | $69.0K | $51.0K | - | - |
| Income Tax | ($859.0K) | - | ($1.09M) | $0 | $0 | - | - | - | $0 | - |
| Net Income | ($14.46M) | - | ($6.40M) | ($1.90M) | ($3.71M) | - | ($2.90M) | ($4.00M) | ($2.43M) | ($5.57M) |
| EPS - Basic | $0.00 | - | $0.00 | $0.00 | $0.00 | - | $0.00 | $0.00 | - | $0.00 |
| EPS - Diluted | $0.00 | - | $0.00 | $0.00 | $0.00 | - | $0.00 | $0.00 | - | $0.00 |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | FY 2024 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.77M | $0 | $2.54M | $2.71M | $2.58M | $2.60M | $2.25M | $4.18M | - | $1.31M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $8.64M | $8.77M | $10.84M | $11.61M | $13.07M | $12.41M | $4.78M | $4.69M | - | $3.21M |
| Current Assets | $3.59M | $5.46M | $2.95M | $3.30M | $3.35M | $2.95M | $2.73M | $5.08M | - | $2.77M |
| Total Assets | $33.89M | $47.89M | $45.38M | $50.91M | $50.96M | $50.56M | $2.73M | $5.08M | - | $2.77M |
| Current Liabilities | $13.41M | $12.35M | $15.57M | $17.14M | $20.91M | $19.91M | $9.43M | $8.78M | - | $6.33M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $19.51M | $19.56M | $22.69M | $25.31M | $29.21M | $28.33M | - | $24.03M | - | - |
| Stockholders' Equity | $14.38M | $28.33M | $22.69M | $25.61M | $21.75M | $22.23M | $213.0K | ($3.70M) | - | $6.56M |
| Retained Earnings | ($279.00M) | ($264.55M) | ($259.25M) | ($252.85M) | ($250.96M) | ($247.25M) | ($243.48M) | ($240.59M) | - | ($233.03M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | FY 2024 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.49M) | - | - | - | ($2.15M) | - | - | - | - | ($4.04M) |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $53.0K | - | - | - | $2.13M | - | - | - | - | $1.51M |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | FY 2024 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -42.7% | - | -14.1% | -3.7% | -7.3% | - | -105.9% | -78.8% | - | -200.8% |
| Return on equity | -100.5% | - | -28.2% | -7.4% | -17.0% | - | -1359.2% | 108.0% | - | -84.8% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.27 | 0.44 | 0.19 | 0.19 | 0.16 | 0.15 | 0.29 | 0.58 | - | 0.44 |
| Quick ratio | 0.27 | 0.44 | 0.19 | 0.19 | 0.16 | 0.15 | 0.29 | 0.58 | - | 0.44 |
| Cash ratio | 0.21 | 0.00 | 0.16 | 0.16 | 0.12 | 0.13 | 0.24 | 0.48 | - | 0.21 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -258.3x | - | -74.0x | -61.2x | -64.1x | - | -42.4x | -146.1x | - | - |
| Equity multiplier | 2.36 | 1.69 | 2.00 | 1.99 | 2.34 | 2.27 | 12.84 | -1.37 | - | 0.42 |
| Liabilities / Assets | 0.58 | 0.41 | 0.50 | 0.50 | 0.57 | 0.56 | - | 4.73 | - | - |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 42531.2x | - | 116330.1x | 115046.8x | 124509.3x | - | 5604669.6x | - | - | 152965.2x |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -347.0% | - | -153.0% | 58.1% | 41.1% | - | - | - | - | - |
| Net income growth (YoY) | -290.1% | - | -121.1% | 52.6% | 33.4% | - | - | - | 59.0% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -33.9% | 27.4% | 10551.2% | - | 231.4% | - | - | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Akari Therapeutics Plc against the 5 most active filers in the same SIC group.